Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticlePediatric Rheumatology

Malignancy in Pediatric-onset Systemic Lupus Erythematosus

Sasha Bernatsky, Ann E. Clarke, Omid Zahedi Niaki, Jeremy Labrecque, Laura E. Schanberg, Earl D. Silverman, Kristen Hayward, Lisa Imundo, Hermine I. Brunner, Kathleen A. Haines, Randy Q. Cron, Kiem Oen, Linda Wagner-Weiner, Alan M. Rosenberg, Kathleen M. O’Neil, Ciarán M. Duffy, Emily von Scheven, Lawrence Joseph, Jennifer L. Lee and Rosalind Ramsey-Goldman
The Journal of Rheumatology October 2017, 44 (10) 1484-1486; DOI: https://doi.org/10.3899/jrheum.170179
Sasha Bernatsky
From the Research Institute of the McGill University Health Centre, Montreal, Quebec; University of Calgary, Calgary, Alberta; The Hospital for Sick Children, Hospital for Sick Children Research Institute, University of Toronto, Toronto; Children’s Hospital of Eastern Ontario, Ottawa, Ontario; University of Manitoba, Winnipeg, Manitoba; University of Saskatchewan, Saskatoon, Saskatchewan, Canada; Duke University Medical Center, Durham, North Carolina; Seattle Children’s Hospital, Seattle, Washington; Columbia University Medical Center, New York, New York; Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; Hackensack University Medical Center, Hackensack, New Jersey; University of Alabama at Birmingham, Birmingham, Alabama; University of Chicago; Northwestern University Feinberg School of Medicine, Chicago, Illinois; Riley Hospital for Children, Indianapolis, Indiana; University of California, San Francisco, San Francisco, California, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sasha.bernatsky@mcgill.ca
Ann E. Clarke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Omid Zahedi Niaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy Labrecque
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura E. Schanberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Earl D. Silverman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristen Hayward
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Imundo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hermine I. Brunner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen A. Haines
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Randy Q. Cron
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kiem Oen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda Wagner-Weiner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan M. Rosenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen M. O’Neil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ciarán M. Duffy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily von Scheven
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence Joseph
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer L. Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosalind Ramsey-Goldman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To determine cancer incidence in a large pediatric-onset systemic lupus erythematosus (SLE) population.

Methods. Data were examined from 12 pediatric SLE registries in North America. Patients were linked to their regional cancer registries to detect cancers observed after cohort entry, defined as date first seen in the clinic. The expected number of malignancies was obtained by multiplying the person-years in the cohort (defined from cohort entry to end of followup) by the geographically matched age-, sex-, and calendar year–specific cancer rates. The standardized incidence ratio (SIR; ratio of cancers observed to expected) was generated, with 95% CI.

Results. A total of 1168 patients were identified from the registries. The mean age at cohort entry was 13 years (SD 3.3), and 83.7% of the subjects were female. The mean duration of followup was 7.6 years, resulting in a total observation period of 8839 years spanning the calendar period 1974–2009. During followup, fourteen invasive cancers occurred (1.6 cancers per 1000 person-yrs, SIR 4.13, 95% CI 2.26–6.93). Three of these were hematologic (all lymphomas), resulting in an SIR for hematologic cancers of 4.68 (95% CI 0.96–13.67). SIR were increased for both male and female patients, and across age groups.

Conclusion. Although cancer remains a relatively rare outcome in pediatric-onset SLE, our data do suggest an increase in cancer for patients followed an average of 7.6 years. About one-fifth of the cancers were hematologic. Longer followup, and study of drug effects and disease activity, is warranted.

Key Indexing Terms:
  • CANCER
  • PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS
  • CHILDHOOD-ONSET SLE
  • MALIGNANCY

Several reports have been published over the past decade examining malignancy risk in rheumatic disease populations. To date, the only cohort study published specifically on pediatric-onset systemic lupus erythematosus (SLE) was the preliminary report of our multicenter cohort1. The objective of our current report is to present the final updated analyses on cancer incidence in an expanded multicentered clinical population of pediatric-onset SLE, including previously analyzed data as well as data from 3 additional centers.

MATERIALS AND METHODS

Our analyses included 4 pediatric rheumatology clinics in Canada and 8 in the United States (Table 1). Patients were linked to their regional cancer registries to detect observed cancers occurring after cohort entry, defined as date first seen in the SLE clinic. The end of followup was defined as the date of cancer registry linkage, thus allowing the inclusion of subjects who reached adulthood. The expected number of malignancies was obtained by multiplying the person-years in the cohort (defined from cohort entry to end of followup) by the geographically matched age-, sex-, and calendar year–specific cancer rates, and summing overall person-years of observation.

View this table:
  • View inline
  • View popup
Table 1.

List of participating centers.

The standardized incidence ratio (SIR; ratio of cancers observed to expected) was generated for overall malignancies and for hematologic malignancies, along with 95% CI, based on the assumption of cancer occurrence as a Poisson-distributed variable. Results were also stratified by sex and age group of person-time (categorized into 0–19 and ≥ 20 yrs of age).

The study was approved by the ethics boards of all participating institutions including the McGill University Health Centre ethics review board (#GEN-06-031).

RESULTS

Across the 12 cohorts, there was a total of 1168 patients. The mean age at cohort entry was 13 years (SD 3.3), and 83.7% of the subjects were female. The mean duration of followup was 7.6 years (SD 6.4, interquartile range 3.4–10.0 yrs), resulting in a total observation period of 8839 years during the calendar period of 1974 to 2009. During the followup period, 14 invasive cancers occurred, compared with 3.39 expected (4.13, 95% CI 2.26–6.93). Three were hematologic malignancies [all non-Hodgkin lymphoma (NHL)], and the other cancers included 2 head and neck squamous cell carcinomas (tongue and nasopharynx) and 1 each of glioblastoma, thyroid cancer (papillary adenoma), breast cancer (infiltrating duct carcinoma), adenocarcinoma not otherwise specified, and 3 cancers whose morphology and histology codes were indeterminate. We did not detect multiple malignancies in the same subjects.

The SIR for NHL was increased at 18.6 (95% CI 3.84–54.4). One of the malignancies occurred in the first year of followup. Nevertheless, excluding all events and person-time in the first year of followup, the SIR for cancer remained elevated at 4.35 (95% CI 2.31–7.44).

Stratifying by sex, the SIR for all cancers was 6.26 (95% CI 1.29–18.28) in males and 3.78 (95% CI 1.89–6.76) in females. For cancer overall, stratifying results according to person-time contributed within age groups, the SIR was 3.29 (95% CI 0.68–9.62) for events and person-time occurring up to age 20, which was similar to the SIR for events and person-time occurring after the age of 20 (SIR 4.44, 95% CI 2.22–7.94).

DISCUSSION

Our present study contributes novel and compelling data on increased malignancy risk in pediatric-onset SLE. Comparing the cancer rates in 1168 patients from 12 centers, the data suggest a higher cancer risk in pediatric-onset SLE versus the general population, which confirms our earlier preliminary report1. The increase in cancer in pediatric-onset SLE appears in part to be driven by hematologic malignancies, which is similar to what is known in adults with SLE2. Of course, in absolute terms, this still translates into relatively few events (1.6 cancers per 1000 person-yrs), which is somewhat reassuring.

A limitation of our study is that patients may have developed cancer after relocating to another state or province, leading to underrepresentation of the true cancer incidence in this cohort. If that underrepresentation was present to a significant degree, it would likely bias the results toward the null. Thus, this potential limitation does not likely explain the results.

Unfortunately, we are unable to comment on the relative importance of SLE disease activity itself, versus the effect of therapeutic drugs. In adults with SLE, we have found mainly an association between lymphoma and cyclophosphamide, and possibly cumulative steroid use, though not specifically with disease activity3. We are also unable to evaluate the effects of race/ethnicity, or of SLE clinical factors such as type of organ involvement and cumulative disease activity, because those data were not available from all the centers participating in our study.

The few published case reports of malignancy in pediatric-onset SLE4,5,6 have documented Hodgkin lymphoma, NHL, and acute lymphoblastic leukemia (ALL). The 3 lymphoma cases in the literature occurred in teenagers after several years of SLE duration, while the fourth case (ALL) occurred in a 6-year-old within 1 year of SLE diagnosis. Two additional case reports described the simultaneous presentation of pediatric-onset SLE (fulfilling the American College of Rheumatology criteria) and ALL, at ages 3 and 77,8. As we noted in our earlier manuscript1, this suggests that there may be a bimodal age-related pattern of hematological malignancies in pediatric-onset SLE. Alternatively, the first peak might actually represent, at least in part, paraneoplastic presentations masquerading as pediatric-onset SLE. As noted, when we excluded the malignancies (and person-time) that occurred in the first year after the SLE diagnosis, the SIR remained elevated.

In terms of a comparison with what is known in adults, an increased hematologic cancer risk has also been demonstrated in adults with SLE (especially NHL, with an SIR 4.39, 95% CI 3.46–5.49 in adults2). Interestingly, in those analyses, adult patients with SLE with the highest cancer risk relative to the general population were in the youngest age group (below age 40 yrs), perhaps supporting the risk of cancer associated with the cumulative burden of SLE and its treatment. These data may also suggest moderating effects for age (of SLE onset) on cancer risk, with greater cancer risk in a developing child versus an adult.

In our pediatric-onset SLE population, the point estimate for the NHL SIR was higher than current estimates for NHL relative risk in adult-onset SLE. However, the 95% CI for our NHL SIR estimate was very wide, and so it is not possible to definitively conclude that the relative risk of NHL in pediatric-onset SLE is higher than in adult-onset SLE. Unlike many cancers in adults, childhood cancers are often not strongly linked to lifestyle or environmental risk factors, but instead may be more likely the result of genetic factors9. Though it is unlikely that a single genetic factor explains the link between NHL and SLE, we are beginning to understand some of the potential genetic links between malignancy and adult SLE10.

There is also current interest in malignancy risk for other pediatric-onset rheumatic diseases, including juvenile idiopathic arthritis (JIA). Using methods similar to the current study, we found rather different results in JIA, with 9 cancers observed in 5294 patients over 36,063 person-years, and an overall SIR that was not elevated11. Still, in those juvenile arthritis analyses, 3 of the 9 cancers were hematologic, potentially representing a signal for an increased risk of hematological cancer in juvenile arthritis, although it is not as striking as what we saw in our current analyses of pediatric-onset SLE.

In our analysis of the largest ever sample of patients with pediatric-onset SLE followed at 12 centers in North America, using tumor registry linkage, cancer was a relatively infrequent outcome. However, the analyses are consistent with an increased risk of cancer compared to the general population, which appears to be driven at least in part by hematologic risk. Longer followup of this population is necessary to accurately identify cancer risk in the later adult years. Additional efforts to evaluate the effects of race/ethnicity, or of clinical factors (such as type of organ involvement, disease activity, and drug exposures) on malignancy risk may help to better guide the care of patients with pediatric-onset SLE.

Footnotes

  • Funded by the Canadian Institutes of Health MOP-106431 and the National Institutes of Health 5R03CA149970-2.

  • Accepted for publication June 7, 2017.

REFERENCES

  1. 1.↵
    1. Bernatsky S,
    2. Clarke AE,
    3. Labrecque J,
    4. von Scheven E,
    5. Schanberg LE,
    6. Silverman ED,
    7. et al.
    Cancer risk in childhood-onset systemic lupus. Arthritis Res Ther 2013;15:R198.
    OpenUrl
  2. 2.↵
    1. Bernatsky S,
    2. Ramsey-Goldman R,
    3. Labrecque J,
    4. Joseph L,
    5. Boivin JF,
    6. Petri M,
    7. et al.
    Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 2013;42:130–5.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Bernatsky S,
    2. Ramsey-Goldman R,
    3. Joseph L,
    4. Boivin JF,
    5. Costenbader KH,
    6. Urowitz MB,
    7. et al.
    Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis 2014;73:138–42.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Gokce M,
    2. Bulus D,
    3. Bilginer Y,
    4. Gumruk F,
    5. Besbas N,
    6. Cetin M
    . Acute lymphoblastic leukaemia in a child with systemic lupus erythematosus. Lupus 2012;21:910–3.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Merino R,
    2. de Inocencio J,
    3. Garcia-Miguel P,
    4. Garcia-Consuegra J
    . Lymphoproliferative disorders in paediatric rheumatic diseases. A report of two cases. Clin Exp Rheumatol 2004;22:649–50.
    OpenUrlPubMed
  6. 6.↵
    1. Posner MA,
    2. Gloster ES,
    3. Bonagura VR,
    4. Valacer DJ,
    5. Ilowite NT
    . Burkitt’s lymphoma in a patient with systemic lupus erythematosus. J Rheumatol 1990;17:380–2.
    OpenUrlPubMed
  7. 7.↵
    1. Maheshwari A,
    2. Pandey M,
    3. Rath B,
    4. Chandra J,
    5. Singh S,
    6. Sharma S
    . Clinical and laboratory observation systemic lupus erythematosus and acute lymphocytic leukemia: An unusual case. Indian J Med Paediatr Oncol 2011;32:154–6.
    OpenUrlPubMed
  8. 8.↵
    1. Saulsbury FT,
    2. Sabio H,
    3. Conrad D,
    4. Kesler RW,
    5. Levien MG
    . Acute leukemia with features of systemic lupus erythematosus. J Pediatr 1984;105:57–9.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Roschewski MJ,
    2. Wilson WH
    . Chapter 106: Non-Hodgkin lymphoma. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, editors. Abeloff’s clinical oncology. 5th ed. Philadelphia: Elsevier; 2014.
  10. 10.↵
    1. Bernatsky S,
    2. Spinelli J,
    3. Gaffney PM,
    4. Smedby KE,
    5. Ramsey-Goldman R,
    6. Wang S,
    7. et al.
    Lupus-related SNPs and risk of diffuse large B-cell non-Hodgkin lymphoma. Arthritis Rheumatol 2015;67 Suppl 10:763.
    OpenUrl
  11. 11.↵
    1. Zahedi Niaki O,
    2. Clarke AE,
    3. Ramsey-Goldman R,
    4. Yeung RS,
    5. Hayward K,
    6. Oen K,
    7. et al.
    Cancer risk in 5,108 patients with juvenile idiopathic arthritis (JIA). Arthritis Rheumatol 2015;67 Suppl 10:955.
    OpenUrl
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 44, Issue 10
1 Oct 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Malignancy in Pediatric-onset Systemic Lupus Erythematosus
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Malignancy in Pediatric-onset Systemic Lupus Erythematosus
Sasha Bernatsky, Ann E. Clarke, Omid Zahedi Niaki, Jeremy Labrecque, Laura E. Schanberg, Earl D. Silverman, Kristen Hayward, Lisa Imundo, Hermine I. Brunner, Kathleen A. Haines, Randy Q. Cron, Kiem Oen, Linda Wagner-Weiner, Alan M. Rosenberg, Kathleen M. O’Neil, Ciarán M. Duffy, Emily von Scheven, Lawrence Joseph, Jennifer L. Lee, Rosalind Ramsey-Goldman
The Journal of Rheumatology Oct 2017, 44 (10) 1484-1486; DOI: 10.3899/jrheum.170179

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Malignancy in Pediatric-onset Systemic Lupus Erythematosus
Sasha Bernatsky, Ann E. Clarke, Omid Zahedi Niaki, Jeremy Labrecque, Laura E. Schanberg, Earl D. Silverman, Kristen Hayward, Lisa Imundo, Hermine I. Brunner, Kathleen A. Haines, Randy Q. Cron, Kiem Oen, Linda Wagner-Weiner, Alan M. Rosenberg, Kathleen M. O’Neil, Ciarán M. Duffy, Emily von Scheven, Lawrence Joseph, Jennifer L. Lee, Rosalind Ramsey-Goldman
The Journal of Rheumatology Oct 2017, 44 (10) 1484-1486; DOI: 10.3899/jrheum.170179
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Keywords

CANCER
PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS
CHILDHOOD-ONSET SLE
MALIGNANCY

Related Articles

Cited By...

More in this TOC Section

  • Differentially Expressed Inflammation-Regulating MicroRNAs in Oligoarticular Juvenile Idiopathic Arthritis
  • Reliability of the Pediatric Specific Musculoskeletal Ultrasound Scoring Systems for the Elbow, Wrist, and Finger Joints
  • Patient-Reported Outcomes Among Transition-Age Young Adults With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Show more Pediatric Rheumatology

Similar Articles

Keywords

  • cancer
  • pediatric systemic lupus erythematosus
  • CHILDHOOD-ONSET SLE
  • MALIGNANCY

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire